Is Omnicell (OMCL) Expanding OmniSphere Into Nursing Units Enough To Reinforce Its Moat? [Yahoo! Finance]
Omnicell (NASDAQ:OMCL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Omnicell (NASDAQ:OMCL) had its price target raised by analysts at Benchmark Co. from $45.00 to $50.00. They now have a "buy" rating on the stock.
Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript [Seeking Alpha]
Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management